Sort   by:  
 Page size 
UnknownEfficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
Not available
S-EPMC4534523 | biostudies-literature
UnknownPIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Not available
S-EPMC5087318 | biostudies-literature
UnknownCorrelative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Not available
S-EPMC5070556 | biostudies-literature
UnknownImpact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
Not available
S-EPMC5455460 | biostudies-literature
TranscriptomicsGGI: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial
Background: We have previously shown that the Gene expression Grade Index (GGI) was able to identify two subtypes of estrogen receptor (ER)-positive tumors that were associated with statistically distinct clinical outcomes in both untreated and tamoxifen-treated patients. Here, we aim to investigate...
ORGANISM(S): Homo sapiens 
2009-07-09 | E-GEOD-16391 | biostudies-arrayexpress
TranscriptomicsGene expression profiling of human breast cancer during pregnancy
Using a dataset of 54 pregnant and 113 age/stage-matched non-pregnant breast cancer patients with complete clinical and survival data; we evaluated the pattern of hot spot somatic mutations and performed transcriptomic profiling using Sequenom® and Affymetrix®, respectively. Breast cancer molecular ...
ORGANISM(S): Homo sapiens 
2014-09-09 | E-GEOD-53031 | biostudies-arrayexpress
UnknownAdjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Not available
S-EPMC4872016 | biostudies-literature
TranscriptomicsFunctional analyses of miR-210 involvement in the aggressive phenotype of high grade breast tumors
As miR-210 expression is correlated to poor prognosis both in estrogen-positive and in estrogen-negative breast cancer (BC) patients, we aimed to investigate the biological processes regulated by miR-210 and which may elucidate its function in the aggressive phenotype of high grade breast cancer. We...
ORGANISM(S): Homo sapiens 
2011-07-01 | E-GEOD-25162 | biostudies-arrayexpress
GenomicsRNA Editing Genotype
Genotyping using Affymetrix SNP6.0
EGAD00010000847 | EGA
Genomicsena-DATASET-BCTL-03-07-2013-15:15:20:064-67 - samples
Transcriptome sequencing data of tumor and 10 matched normal samples of the EGAS00001000495 project
EGAD00001000627 | EGA
Sort   by:  
 Page size